Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2024 | Story André Damons | Photo André Damons
Prof Martin Nyaga – Associate Professor and Head of the University of the Free State (UFS) Next Generation Sequencing Unit (UFS-NGS) – recently obtained a B3 rating from the National Research Foundation (NRF).

Prof Martin Nyaga – Associate Professor and Head of the University of the Free State (UFS) Next Generation Sequencing (NGS) Unit – recently obtained an NRF B3 rating from the National Research Foundation (NRF), which is not only testament to his research prowess, but also demonstrates his unwavering commitment to academic excellence.

Prof Nyaga made a significant improvement from his previous NRF Y2 rating (categorised as a promising young researcher). His new B3 rating is assigned to a researcher who enjoys considerable international recognition by their peers for the high quality and impact of their recent research output.

“It is an incredibly thrilling experience to attain the esteemed NRF rating in the B category. Accomplishing the NRF B3 rating satiates an enormous sense of being appreciated and acknowledged individually and as an academic at the UFS. This acknowledgement emphasises the high quality of the research that I do and provides immense motivation to continue mentoring upcoming and emerging researchers in the field of molecular virology,” says Prof Nyaga.

Research output

According to him, this recognition serves as motivation to become an NRF A-rated researcher in the next rating cycle. “I am optimistic that I can meet the minimum threshold to be among the highly esteemed NRF A-rated researchers who are internationally recognised as leading scholars in their field of specialisation for their high-quality research and wide impact.”

Prof Nyaga, who is affiliated to the Division of Virology within the Faculty of Health Sciences, has an exponential trajectory in research output dissemination in reputable international conference presentations and scientific/medical journals such as Nature, Nature Medicine, Nature Communications, and Science, among other quantile 1 journals, with significant citations (3 337 times, h-index 20 and i-10 index 32). He has demonstrated unwavering commitment to academic excellence and has made significant strides within his niche research area of whole genome sequencing and metagenomics of enteric and respiratory viruses. He has not only successfully collaborated with eminent researchers both within and outside the university and globally, but his interdisciplinary research approach has led to groundbreaking studies that address complex issues from multiple perspectives.

Prof Nyaga has applied his expertise to address real-world challenges. One notable example is his involvement in community-based projects and public outreach and education. He has organised and participated in various workshops, seminars, and public lectures aimed at disseminating knowledge and raising awareness about important issues in the field of enteric and respiratory pathogen genomics. His efforts have strengthened the ties between the UFS and the broader community, enhancing the impact and visibility of the institution.

Support by the UFS

“Achieving this rating not only required self-driven research-enhancement discipline, networking, and implementation of novel concepts to enhance my NRF research rating from Y to B, but I also received substantial support from my affiliate institution, especially the Faculty of Health Sciences and the Directorate of Research and Development (DRD).”

“The UFS has put in place amazing policies and career development strategies to ensure that focused Y-rated researchers have the opportunity to become established researchers within one rating cycle of five years – a reality that I immensely thank God for enabling me to attain,” says Prof Nyaga.

These programmes include, among others, the Transforming the Professoriate Mentoring Programme, where he was part of the first cohort of members recruited in 2019.

Prof Nyaga, who has supervised/co-supervised seven PhDs and more than 20 master’s and honours postgraduates to graduation, also serves in various leadership roles, including Chairman for the Africa Centres for Disease Control and Prevention (ACDC) Pathogen Genomics Initiative (PGI), Vaccine-Preventable Diseases (VPD) Focus Group (FG), and Director of the WHO Collaborating Centre for VPD Surveillance and Pathogen Genomics. His ability to instigate and inspire as the team lead and his strategic vision for the UFS-NGS Unit are key factors in the successful execution of numerous initiatives. He is a strong advocate for diversity, equity, and inclusion, and his efforts have created a more inclusive and welcoming environment for his peers and students from diverse backgrounds.

Future

He plans to undertake future research that has an impact on the national health systems and to establish himself as an international leader in his niche research area. “I hope to create a vibrant association between research and national development goals and to have a transformative effect on my area of research in a way that can influence policy by addressing national and international challenges within global knowledge innovation,” says Prof Nyaga.

His continuing research involves the use of next generation sequencing to decipher the viral component of the respiratory and enteric milieu and accentuate the critical need to define the complete spectrum of disease-causing viruses. Several previously known and unknown viruses have been detected, including viruses with previously unrecognised tropism.

Additionally, whole genome sequencing of important respiratory viruses, such as the respiratory syncytial virus (RSV) (as part of the respiratory niche) and rotavirus (as part of the enteric niche), is being performed simultaneously for different countries, including South Africa, Zambia, Rwanda, Kenya, Cameroon, Mozambique, and Malawi, to enhance the genomic surveillance of specific respiratory and enteric viruses of interest.

The overall goal is to identify novel pathogens responsible for human viral diseases and to create a flexible and highly effective system for the rapid identification and analysis of emerging or re-emerging agents. This will serve four purposes: (i) improve preparedness for outbreaks, (ii) characterise new viruses, (iii) identify additional new pathogenic viruses, and (iv) provide new understanding of the human respiratory and enteric virome.

“Viruses that appear to be relevant will be prioritised to elucidate specific targets for rapid diagnostics using panels developed from the antigenic sites of the generated genomes, and immune mechanisms used to develop antiviral interventions such as drugs and vaccines,” explains Prof Nyaga.

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation, commented: “The rating bears testimony to the incredibly important and impactful work that Prof Nyaga is undertaking. The solid international footprint of his publications and their citations also confirm the relevance and currency of his cutting-edge work. The UFS is extremely proud of this signal achievement, and we wish him well with his work in the years ahead.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept